Record Details

Development, evaluation, and laboratory validation of immunoassays for the diagnosis of equine infectious anemia (EIA) using recombinant protein produced from a synthetic p26 gene of EIA virus

KRISHI: Publication and Data Inventory Repository

View Archive Info
 
 
Field Value
 
Title Development, evaluation, and laboratory validation of immunoassays for the diagnosis of equine infectious anemia (EIA) using recombinant protein produced from a synthetic p26 gene of EIA virus
 
Creator Harisankar Singha
Sachin K. Goyal
Praveen Malik
Sandip K. Khurana
Raj K. Singh
 
Subject Equine infectious anemia
Recombinant p26 protein
ELISA
Sensitivity
Specificity
 
Description Not Available
Equine infectious anemia (EIA)—a retroviral
disease caused by equine infectious anemia virus (EIAV)—
is a chronic, debilitating disease of horses, mules, and donkeys.
EIAV infection has been reported worldwide and is
recognized as pathogen of significant economic importance
to the horse industry. This disease falls under regulatory
control program in many countries including India. Control
of EIA is based on identification of inapparent carriers by
detection of antibodies to EIAV in serologic tests and
‘‘Stamping Out’’ policy. The current internationally accepted
test for diagnosis of EIA is the agar gel immune-diffusion
test (AGID), which detects antibodies to the major gag
gene (p26) product. The objective of this study was to
develop recombinant p26 based in-house immunoassays
[enzyme linked immunosorbent assays (ELISA), and AGID]
for EIA diagnosis. The synthetic p26 gene of EIAV was
expressed in Escherichia coli and diagnostic potential of
recombinant p26 protein were evaluated in ELISA and
AGID on 7,150 and 1,200 equine serum samples, respectively,
and compared with commercial standard AGID kit.
The relative sensitivity and specificity of the newly developed
ELISA were 100 and 98.6 %, respectively. Whereas,
relative sensitivity and specificity of the newly developed
AGID were in complete agreement in respect to commercial
AGID kit. Here, we have reported the validation of an
ELISA and AGID on large number of equine serum samples
using recombinant p26 protein produced from synthetic
gene which does not require handling of pathogenic EIAV.
Since the indigenously developed reagents would be
economical than commercial diagnostic kit, the rp26 basedimmunoassays
could be adopted for the sero-diagnosis and
control of EIA in India.
ICAR
 
Date 2020-07-31T05:46:49Z
2020-07-31T05:46:49Z
2013-08-08
 
Type Article
 
Identifier Not Available
0970-2822
http://krishi.icar.gov.in/jspui/handle/123456789/38630
 
Language English
 
Publisher Springer